Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: bobbseytwins2001 who wrote (1060)	5/30/2025 3:49:43 PM
From: Maturin	Respond to of 1229

Agree, thank you End2War for a thoughtful post which makes sense based on my own experience that I described in my previous post. Hopefully PSS owns 100% of the debt and the convertible bond arb strategy isn't at play here. For my part I added yesterday and again today.

To: bobbseytwins2001 who wrote (1060)	5/31/2025 1:18:14 PM
From: galt	3 Recommendations Recommended By dorightbythem JJINV urslor Respond to of 1229

Just watched a friend lose his business due to convertible debt. Once the covenants are breached, the path to conversion of the debt to equity is swift and unrelenting. Not sure if this is at play here, as PSS surely has the resources to fund without going to such a draconian measure. I continue to believe in Anktiva but wonder how much longer it can take for either significant sales growth or news that the FDA has seen the light. Personally, would be delighted to see a buyout, but doesn't seem to be a good environment right now, given disdain for small biotechs and an FDA that is in turmoil. As my basis is below 3 and my position is very healthy, I'm content, for now, to sit back and watch. Highly doubt I would buy more unless the share price shows significant improvement. Best